These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39003154)

  • 1. Belantamab-mafodotin-associated keratopathy.
    Khattabi Z; Lesan V; Berger T; Seitz B; Hamon L
    J Fr Ophtalmol; 2024 Nov; 47(9):104253. PubMed ID: 39003154
    [No Abstract]   [Full Text] [Related]  

  • 2. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
    Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
    Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visualization of Keratopathy Associated With the Antibody-Drug Conjugate Belantamab Mafodotin Using Infrared Imaging in Patients With Multiple Myeloma.
    Gallin V; Nölle B; Schub N; Roider J
    Cornea; 2024 Jun; ():. PubMed ID: 38900711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
    Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
    Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management.
    Mickevicius T; Pink AE; Bhogal M; O'Brart D; Robbie SJ
    Cornea; 2023 Apr; 42(4):507-519. PubMed ID: 36525340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
    Offidani M; Corvatta L; Morè S; Olivieri A
    Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography.
    Matsumiya W; Karaca I; Ghoraba H; Akhavanrezayat A; Mobasserian A; Hassan M; Regenold J; Yasar C; Liedtke M; Kitazawa K; Nguyen QD
    Am J Ophthalmol Case Rep; 2021 Sep; 23():101133. PubMed ID: 34169181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.
    Baines AC; Ershler R; Kanapuru B; Xu Q; Shen G; Li L; Ma L; Okusanya OO; Simpson NE; Nguyen W; Theoret MR; Pazdur R; Gormley NJ
    Clin Cancer Res; 2022 Nov; 28(21):4629-4633. PubMed ID: 35736811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy.
    Fazio F; Petrucci MT; Corvatta L; Piciocchi A; Della Pepa R; Tacchetti P; Musso M; Zambello R; Belotti A; Bringhen S; Antonioli E; Conticello C; Renzo ND; De Stefano V; Musto P; Gamberi B; Derudas D; Boccadoro M; Offidani M; Morè S
    EJHaem; 2024 Jun; 5(3):485-493. PubMed ID: 38895069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
    Dimopoulos MA; Hungria VTM; Radinoff A; Delimpasi S; Mikala G; Masszi T; Li J; Capra M; Maiolino A; Pappa V; Chraniuk D; Osipov I; Leleu X; Low M; Matsumoto M; Sule N; Li M; McKeown A; He W; Bright S; Currie B; Perera S; Boyle J; Roy-Ghanta S; Opalinska J; Weisel K
    Lancet Haematol; 2023 Oct; 10(10):e801-e812. PubMed ID: 37793771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
    Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel agent for myeloma causing toxic keratopathy, belantamab mafodotin: a case report and literature review.
    Kurt RA; Gören D; Karadeniz S; Arat M; Sahin A
    Arq Bras Oftalmol; 2022 Nov; 87(4):. PubMed ID: 36350901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study.
    Cardellino A; Correll JR; Martin M; Gorsh B; Sapra S; Popat R
    Front Oncol; 2023; 13():1274659. PubMed ID: 38144529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.
    Iida S; Sunami K; Mishima Y; Fujii T; Kato H; Terao T; Matsuzawa Y; Matsubara M; Crossman T; Kremer BE; Gupta I
    Int J Hematol; 2023 Nov; 118(5):596-608. PubMed ID: 37668832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belantamab mafodotin for relapsed or refractory multiple myeloma.
    Gil-Sierra MD; Briceño-Casado MDP
    J Oncol Pharm Pract; 2022 Sep; 28(6):1375-1380. PubMed ID: 35306910
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
    Shragai T; Magen H; Lavi N; Gatt M; Trestman S; Zektser M; Ganzel C; Jarchowsky O; Berger T; Tadmor T; Leiba M; Hertzog-Tzarfaty K; Horowitz N; Shapira M; Varssano D; Berger Y; Frenkel S; Krauthammer M; Avivi I; Luttwak E; Cohen YC;
    Br J Haematol; 2023 Jan; 200(1):45-53. PubMed ID: 36205375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.
    Ntanasis-Stathopoulos I; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Roussou M; Eleutherakis-Papaiakovou E; Spiliopoulou V; Kastritis E; Terpos E; Dimopoulos MA; Gavriatopoulou M
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Belantamab Mafodotin-Associated Keratopathy With Rigid Gas-Permeable Corneal Contact Lenses.
    Keye P; Engelhardt M; Wäsch R; Böhringer D; Reinhard T
    Cornea; 2023 Jun; 42(6):744-746. PubMed ID: 36728309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience.
    Iula R; De Novellis D; Trastulli F; Della Pepa R; Fontana R; Carobene A; Di Perna M; D'Ambrosio A; Romano M; Leone A; De Fazio L; Fiumarella A; Gaeta G; Marafioti V; Barbato S; Palmieri S; Rocco S; Serio B; Califano C; Pane F; Ferrara F; Giudice V; Selleri C; Catalano L
    Front Oncol; 2022; 12():1026251. PubMed ID: 36457484
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.